Your browser doesn't support javascript.
loading
[Molecular genetic mechanisms of drug resistance in prostate cancer].
Krasnov, G S; Dmitriev, A A; Sadritdinova, A F; Volchenko, N N; Slavnova, E N; Danilova, T V; Snezhkina, A V; Melnikova, N V; Fedorova, M S; Lakunina, V A; Belova, A A; Nyushko, K M; Alekseev, B Y; Kaprin, A D; Kudryavtseva, A V.
Afiliación
  • Krasnov GS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Dmitriev AA; Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
  • Sadritdinova AF; Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, 119121, Russia.
  • Volchenko NN; gskrasnov@mail.ru.
  • Slavnova EN; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Danilova TV; Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
  • Snezhkina AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Melnikova NV; Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
  • Fedorova MS; Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
  • Lakunina VA; Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
  • Belova AA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Nyushko KM; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Alekseev BY; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Kaprin AD; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Kudryavtseva AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
Mol Biol (Mosk) ; 49(5): 716-27, 2015.
Article en Ru | MEDLINE | ID: mdl-26510590
ABSTRACT
The major problem in prostate cancer treatment is the development of drug resistance and especially important, cross-resistance. The mechanisms of drug resistance, which are divided into ligand-dependent (requiring the presence of androgens in the cell) and independent (not requiring the presence of androgens) are reviewed. The mechanisms are mainly represented with mutations of the androgen receptor and expression of aberrant constitutively active splice variants, as well as up-regulation of genes involved in androgens synthesis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Regulación Neoplásica de la Expresión Génica / Resistencia a Múltiples Medicamentos / Resistencia a Antineoplásicos / Antineoplásicos Límite: Humans / Male Idioma: Ru Revista: Mol Biol (Mosk) Año: 2015 Tipo del documento: Article País de afiliación: Rusia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Regulación Neoplásica de la Expresión Génica / Resistencia a Múltiples Medicamentos / Resistencia a Antineoplásicos / Antineoplásicos Límite: Humans / Male Idioma: Ru Revista: Mol Biol (Mosk) Año: 2015 Tipo del documento: Article País de afiliación: Rusia